Anlon Healthcare IPO to open Tuesday: 10 key things you need to know about RHP before you subscribe to £ 121 Crore issue

Anlon Healthcare IPO in Focus: Anlon Healthcare Initial Public Affering (IPO) is scheduled to kick off for subscription on Tuesday, August 26 and will remain open until Thursday, August 29. The company intends to increase £ 121 through the offer, which is entirely a new issue of 1.33 crore shares. The IPO price tire is at £ 86 at £ 91 a share. Retail investors can apply in one lot for at least 164 shares and can apply for up to 13 lots. At the top of the IPO price band, £ 91 each, retail investors should make a minimum investment of £ 14.924 per lot. Let’s look at some of the key points mentioned in the Anlon Healthcare RHP: About Company: Anlon Healthcare is a chemical manufacturing business involved in producing advanced pharmaceutical interproducts with high purity, which serves as raw materials/important starting materials in the production of active pharmaceuticals (APIs). These APIs, in turn, serve as raw materials for pharmaceutical formulations in the preparation of different types of completed dose forms (FDF), such as tablets, capsules, ointments and syrups, as well as ingredients in nutritional formulations, personal care products and animal products. Product portfolio: The product portfolio consists of sixty-five (65) commercialized products, twenty-eight (28) products in the lead stage, and forty-nine (49) products on the laboratory testing/laboratory stage, from the date of submission of the RHP. For fiscal 2025, fiscal 2024 and fiscal 2023, the company made 338 MT, 153 MT and 316 MT APIs and pharmaceutical interproducts up to 38, 39 and 48 customers respectively. Unique presence: The business is one of the few manufacturers of Loxoprofen-Sodium Dihydrate in India, a significant API widely used in the treatment of pain and inflammation associated with conditions, including rheumatoid arthritis, osteoarthritis, lower back pain, frozen shoulder, neck-to-shoulder syndrome, teeth pain, or post-sour. D&B report. Global approvals: The API product, Loxoprofen -Nodium Dihydrate, has been approved by regulatory authorities in Brazil, Japan and China. The current position as one of the few manufacturers of Loxoprofen -Sodium Dihydrate in India enables it to serve clients in these jurisdictions. Furthermore, the company has submitted DMFs for various products for different products with regulatory authorities in the European Union, Russia, Japan, South Korea, Iran, Jordan and Pakistan. It is also in the process of submitting DMFs for the approval of ketoprofen with the US regulatory authority and Dexketoprofen rometamol with regulatory authorities in Spain, Italy, Germany and Slovenia. In addition to producing pharmaceutical intermediary and APIs in accordance with the manufacture of pharmaceutical intermediary and APIs in accordance with different domestic and international standards, the company recently began undertaking customized manufacturing services for complicated or new chemical compounds, which have adapted to the manufacturing process to meet specific customers’ purity levels that exceed industry standards. It also undertakes API development, preparation and submission of drug master files (DMFs) in the Indian and world markets according to the pharmacopic requirements of clients and regulatory agencies. Customers in 15 countries reach: The company supplies its products in both domestic and overseas markets to various pharmaceutical businesses, third-party dealers and distributors. In addition to its domestic market sales in India, he has its operations and global footprints with clients in more than 15 countries, including Italy, Germany, South Korea, China, Argentina, Chile, Colombia, Mexico, Egypt, Turkey, Japan, Brazil, the United Kingdom and the United Arabic Emirates. Objectives of the issue: The company suggests that the returns for financing capital expenditure requirements for the proposed expansion, complete or partial repayment and/or prepayment of certain outstanding security loans (term loans) are used, used by the company, finance its working capital requirements and for general corporate purposes. IMPORTANT RISKS: Revenue from the business from operations depends on a limited number of customers. The loss of any of these customers or the loss of income from any of these customers can have a significant adverse effect on the business’s business, financial condition, operational results and cash flow. Assignment and listing details: The granting of shares is expected to be completed on September 01, 2025, with a preliminary listing on both the BSE and NSE scheduled for Tuesday, September 3, 2025. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or brokerage companies, and not of currency. We advise investors to check with certified experts before making investment decisions.